Investing in biotech companies, especially relatively small ones, can be a double-edged sword. On the one hand, these stocks often carry massive upside potential, provided things work in their favor. However, this potential comes with elevated risks, so investors should always be cautious when considering investing in smaller companies in the industry.

With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). These companies' ongoing developments could fuel huge runs in 2023.

Continue reading

Source Fool.com